Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma (VCR)
|ClinicalTrials.gov Identifier: NCT00980395|
Recruitment Status : Active, not recruiting
First Posted : September 21, 2009
Last Update Posted : December 5, 2017
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with cladribine and rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine and rituximab works in treating patients with advanced mantle cell lymphoma or indolent lymphoma.
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma Mantle Cell Lymphoma Indolent Lymphoma SLL||Drug: rituximab Drug: bortezomib Drug: cladribine||Phase 2|
- Determine the 2-year progression-free survival of patients with advanced mantle cell lymphoma or indolent lymphoma treated with bortezomib, cladribine, and rituximab.
- Determine the 2-year overall survival of patients treated with this regimen.
- Determine the complete response and overall response rate in patients treated with this regimen.
- Describe the long- and short-term toxicity of this regimen in these patients.
- Determine the prognostic importance of Aurora kinase A in patients treated with this regimen.
- Determine the cytokine profiles for each lymphoma subtype and how they change with this regimen.
- Evaluate the prognostic importance of major carcinogenic pathways using tissue microarray.
OUTLINE: Patients receive bortezomib IV on days 1 and 4, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Blood samples are collected at baseline and after course 1 for cytokine profile studies. Previously collected tissue samples are obtained for analysis of Aurora kinase A and B, Ki-67, cyclin D, Bcl-2, phosphor-HisH3, c-Met, and VEGF expression by using tissue microarray (IHC staining), reverse transcriptase-PCR, and/or western blotting.
After completion of study therapy, patients are followed up every 3 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas|
|Actual Study Start Date :||July 7, 2009|
|Primary Completion Date :||September 12, 2014|
|Estimated Study Completion Date :||December 31, 2021|
Experimental: VCR (Velcade, Cladribine and Rituximab)
375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
Other Name: RituxanDrug: bortezomib
1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
Other Name: VelcadeDrug: cladribine
4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
Other Name: Leustatin
- Progression-free survival at 2 years [ Time Frame: 2 years ]
- Overall survival at 2 years [ Time Frame: 2 years ]
- Complete response and overall response rate [ Time Frame: After treatment ]
- Long- and short-term toxicity [ Time Frame: During and after treatment ]
- Cytokine profiles [ Time Frame: After treatment ]
- Prognostic importance of Aurora kinase A [ Time Frame: After treatment ]
- Prognostic importance of major carcinogenic pathways [ Time Frame: After treatment ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00980395
|United States, Arizona|
|The University of Arizona Cancer Center|
|Tucson, Arizona, United States, 85724-5024|
|Principal Investigator:||Daniel O. Persky, MD||University of Arizona|